Anti-VEEV Spike glycoprotein Antibody (SKV16)

Anti-VEEV Spike glycoprotein Antibody (SKV16)

The Anti-VEEV Spike glycoprotein Antibody (SKV16) is a highly specific and sensitive antibody designed to target the VEEV spike glycoprotein. This powerful antibody has been extensively tested and validated for its effectiveness in detecting and neutralizing the VEEV virus.

The VEEV spike glycoprotein is a key component of the Venezuelan equine encephalitis virus (VEEV), a mosquito-borne virus that can cause severe illness in humans and animals. This protein is responsible for the virus’s ability to enter and infect host cells, making it a critical target for treatment and prevention strategies.

Main Applications

• Detection and diagnosis of VEEV infections: The Anti-VEEV Spike glycoprotein Antibody (SKV16) is an essential tool for detecting and diagnosing VEEV infections. Its high specificity and sensitivity make it an ideal choice for use in diagnostic tests, such as ELISA and Western blotting.
• Therapeutic use: This antibody can also be used as a therapeutic agent for treating VEEV infections. By targeting the spike glycoprotein, it can effectively block the virus’s entry into host cells, preventing the spread of infection.
• Research: The Anti-VEEV Spike glycoprotein Antibody (SKV16) is a valuable research tool for studying the VEEV virus and its mechanisms of infection. It can be used in various experimental techniques, including immunofluorescence, immunohistochemistry, and flow cytometry.
• Antiviral drug screening: This antibody can also be used in antiviral drug screening assays to identify compounds that can inhibit the VEEV spike glycoprotein and prevent viral entry.
• Pathogenesis studies: By using the Anti-VEEV Spike glycoprotein Antibody (SKV16) in animal models, researchers can gain a better understanding of VEEV’s pathogenesis and potential treatment options.

In conclusion, the Anti-VEEV Spike glycoprotein Antibody (SKV16) is a highly specific and sensitive antibody that plays a crucial role in the detection, treatment, and research of VEEV infections. Its use in various applications and experimental techniques makes it an essential tool for the biotech industry. Trust in its reliability and accuracy to support your research and development efforts in the fight against VEEV.

Experimental Use Cases

• Vaccine development: The Anti-VEEV Spike glycoprotein Antibody (SKV16) can be used to evaluate the efficacy of potential VEEV vaccines. By testing the antibody’s ability to neutralize the virus, researchers can determine the best vaccine candidates for further development.

ProteoGenix catalogue number ARO-A22969. For research use only.

Target: E1 envelope glycoprotein, E2 envelope glycoprotein, EC:3.4.21.90, Precursor of protein E3/E2, Spike glycoprotein E1, Spike glycoprotein E2, Structural polyprotein, p130, p62, pE2; Clonality: Monoclonal Antibody; Applications: Neutralization, ELISA.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet